Dietary fibre intervention for gut microbiota, sleep, and mental health in adults with irritable bowel syndrome: A scoping review by Yan, Ran et al.
Edith Cowan University 
Research Online 
ECU Publications Post 2013 
2021 
Dietary fibre intervention for gut microbiota, sleep, and mental 
health in adults with irritable bowel syndrome: A scoping review 
Ran Yan 
Edith Cowan University 
Lesley J. Andrew 
Edith Cowan University 
Evania Marlow 
Edith Cowan University 
Kanita Kunaratnam 
Edith Cowan University 
Amanda Devine 
Edith Cowan University 
See next page for additional authors 
Follow this and additional works at: https://ro.ecu.edu.au/ecuworkspost2013 
10.3390/nu13072159 
Yan, R., Andrew, L., Marlow, E., Kunaratnam, K., Devine, A., Dunican, I. C., & Christophersen, C. T. (2021). Dietary fibre 
intervention for gut microbiota, sleep, and mental health in adults with irritable bowel syndrome: A scoping review. 
Nutrients, 13(7), article 2159. https://doi.org/10.3390/nu13072159 
This Journal Article is posted at Research Online. 
https://ro.ecu.edu.au/ecuworkspost2013/10399 
Authors 
Ran Yan, Lesley J. Andrew, Evania Marlow, Kanita Kunaratnam, Amanda Devine, Ian C. Dunican, and Claus 
T. Christophersen 
This journal article is available at Research Online: https://ro.ecu.edu.au/ecuworkspost2013/10399 
nutrients
Review
Dietary Fibre Intervention for Gut Microbiota, Sleep, and
Mental Health in Adults with Irritable Bowel Syndrome:
A Scoping Review
Ran Yan 1,2,*, Lesley Andrew 1,2 , Evania Marlow 1, Kanita Kunaratnam 1,2, Amanda Devine 1,2 ,
Ian C. Dunican 1 and Claus T. Christophersen 1,3,4


Citation: Yan, R.; Andrew, L.;
Marlow, E.; Kunaratnam, K.; Devine,
A.; Dunican, I.C.; Christophersen, C.T.
Dietary Fibre Intervention for Gut
Microbiota, Sleep, and Mental Health
in Adults with Irritable Bowel
Syndrome: A Scoping Review.
Nutrients 2021, 13, 2159. https://
doi.org/10.3390/nu13072159
Academic Editors: Liborio Parrino
and Francesca Scazzina
Received: 25 May 2021
Accepted: 18 June 2021
Published: 23 June 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 School of Medical and Health Sciences, Edith Cowan University, Joondalup Drive, Perth 6027, Australia;
l.andrew@ecu.edu.au (L.A.); e.marlow@ecu.edu.au (E.M.); k.kunaratnam@ecu.edu.au (K.K.);
a.devine@ecu.edu.au (A.D.); i.dunican@ecu.edu.au (I.C.D.); c.christophersen@ecu.edu.au (C.T.C.)
2 Institute for Nutrition Research, Edith Cowan University, Joondalup Drive, Perth 6027, Australia
3 WA Human Microbiome Collaboration Centre, School of Molecular and Life Sciences, Curtin University,
Kent Street, Perth 6102, Australia
4 Integrative Metabolomics and Computational Biology Centre, Edith Cowan University, Joondalup Drive,
Perth 6027, Australia
* Correspondence: r.yan@ecu.edu.au; Tel.: +61-8-6304-5579
Abstract: Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder affecting
4–5% of the global population. This disorder is associated with gut microbiota, diet, sleep, and
mental health. This scoping review therefore aims to map existing research that has administrated
fibre-related dietary intervention to IBS individuals and reported outcomes on at least two of the three
following themes: gut microbiota, sleep, and mental health. Five digital databases were searched to
identify and select papers as per the inclusion and exclusion criteria. Five articles were included in the
assessment, where none reported on all three themes or the combination of gut microbiota and sleep.
Two studies identified alterations in gut microbiota and mental health with fibre supplementation.
The other three studies reported on mental health and sleep outcomes using subjective questionnaires.
IBS-related research lacks system biology-type studies targeting gut microbiota, sleep, and mental
health in patients undergoing diet intervention. Further IBS research is required to explore how
human gut microbiota functions (such as short-chain fatty acids) in sleep and mental health, following
the implementation of dietary pattern alteration or component supplementation. Additionally, the
application of objective sleep assessments is required in order to detect sleep change with more
accuracy and less bias.
Keywords: IBS; FODMAP; dietary fibre; gut microbiota; sleep; mental health; short-chain fatty acid
1. Introduction
1.1. Irritable Bowel Syndrome
Irritable bowel syndrome (IBS), a common functional gastrointestinal disorder, is
characterised by recurrent abdominal pain and alterations in bowel habits that include
the coexistence of bloating, flatulence, and abdominal distention [1]. According to the
symptom-based Rome IV diagnostic criteria, IBS can be subtyped into four categories:
constipation dominant (IBS-C), diarrhoea dominant (IBS-D), mixed IBS (IBS-M), and un-
subtyped (IBS-U) [2]. Globally, IBS had previously been estimated to affect 11–12% of
the population [3], where this figure was corrected to 4–5% following the introduction of
the Rome IV criteria in 2016 [4,5], such as 4.7% of adults in the United States, 4.6% in the
United Kingdom, 4.5% in Canada [4]. According to a population-based cross-sectional
survey, 7.9 % of Australian adults have a self-reported medical diagnosis of IBS [6]. Even
though the aetiology of IBS remains unclear, emerging evidence suggests that IBS may be
one of the disorders of gut-brain interaction [7,8], engaging homeostasis regulation via
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the gut-brain-microbiome axis [9,10]. Research to date suggests that 44% of IBS patients
have associated mental health disorders, including depression and anxiety [11,12], where
37.6% of IBS patients have reported sleep problems, such as sleep fragmentation, poor sleep
quality or reduced sleep duration [13–15]. There is also evidence to suggest and support
that IBS is related to gut dysbiosis (unbalanced microbiota that lack microbial diversity and
temporal instability [16]), leading to subtype-specific and symptom-relevant alterations in
gut microbiota [17].
A survey of United States (U.S.) gastroenterologists has reported that 85% perceived
a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols
(FODMAP) to be very/somewhat effective as a dietary therapy, where roughly three
out of four IBS patients were consequently recommended to implement a low-FODMAP
diet [18]. The survey also found that more than 50% of IBS patients always (13.8%)/usually
(38.8%) intended to manage their IBS symptoms by themselves before seeking advice
from a gastroenterologist [18]. The American College of Gastroenterology suggests a
low-FODMAP diet as a means of improving global symptoms in people with IBS [19].
1.2. The Low-FODMAP Diet
A low-FODMAP diet (LFD) is an effective way to reduce gut symptoms in people
with IBS [20–22]. Technically, the diet is made up of three phases: elimination/restriction
(2–6 weeks), reintroduction, and personalisation, which help patients to target personal
trigger foods, to identify individual tolerance levels, and to self-manage their symptoms
in their daily life [23,24]. The effectiveness (self-reportedly adequate symptom control)
of a 3/4-week LFD intervention can be up to 68–81% [22,25]. Similarly, in an Irish cohort
study, 66% (86/127), 72% (53/74), and 76% (31/41) of patients reported being satisfied
with the overall symptomatic improvement of an LFD at follow-up stages of 3, 6, and
12 months, respectively [26]. Accordingly, only 11% (14/127) of participants were willing
to be re-introduced to high FODMAP foods at the 3-month follow-up because of their fear
of recurrence of symptoms, where 81.1% (n = 60/74) and 70.7% (n = 29/41) continued the
exclusion/restricted LFD at 6-month and 12-month follow-up, respectively [26].
Gastrointestinal dysbiosis has been confirmed as a characteristic of IBS, where Lac-
tobacillus and Bifidobacterium are deficient in people with IBS when compared to healthy
populations [27]. An LFD or reduced FODMAP intake can reduce bifidobacteria but does
not necessarily normalise the dysbiotic gut environment [28,29]. A 4-week LFD has been
shown to lead to an increased dysbiosis in 42% of people with IBS, and 46% had no change
in dysbiosis after the 4-week LFD [30]. A recent systematic review has demonstrated that
restriction of FODMAP intake, either in healthy subjects or patients with intestinal diseases,
including IBS, can induce microbial alteration associated with dysbiosis, compared to
prebiotic supplementation [28]. However, the microbial signature related to IBS symptom
severity was not found to be associated with intake of FODMAP but rather negatively
associated with microbial richness [31].
When combined, despite the symptomatic improvement of an LFD in the majority
of IBS patients, further research is still required to examine the long-term effects on gut
health as many IBS sufferers are reluctant to re-introduce trigger foods. If patients do not
manage to replace high FODMAP foods with suitable low-FODMAP alternatives, they
may also be reducing fibre intake simultaneously [23,32]. Therefore, in this scoping review,
the low-FODMAP diet is regarded as a dietary fibre-related intervention.
1.3. Current Guidelines of Fibre Use in People with IBS
Modification of (not simply increasing or decreasing) fibre intake is one of the general
dietary messages from NICE guidelines for dietary management in those with IBS since
certain types of dietary fibres are not well tolerated, such as wheat bran [33]. Moreover,
the dietary adjustment requires consideration of patients’ subtype, symptoms profile, and
individual triggers.
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Australian dietary guidelines currently recommend a suggested dietary target (SDT)
daily fibre intake of 38 g for men and 28 g for women in order to reduce chronic disease
risk, where adequate intake (AI) values for male adults is set at 30 g and for female adults
at 25 g [34]. In a randomised controlled trial (RCT) of LFD intervention, only 6 (5%) IBS
participants habitual intake achieved the U.K. national recommendation (30 g/d) [35]. In
a French adult cohort, both healthy controls (n = 34,578) and people with IBS (n = 1870)
were found to consume lower fibre intake than recommended (25 g/day), at mean levels
of 19.4 g and 19.3 g, respectively [36]. A lower fibre intake can be problematic; healthy
individuals who switched from a high-fibre diet to a low-fibre, high-sugar diet decreased
their microbial diversity and increased permeability in their small intestine [37]. Increased
permeability and impaired epithelial barrier function are often observed in the small and
large bowel of IBS patients, especially in IBS-D [8,38,39].
Many reviews have elaborated on the types and characteristics of dietary fibre as
well as mechanisms of action and benefits [40]. Fibre can come from natural food, such
as vegetables, fruits, legumes, and nuts, as well as in supplement form where specific
health benefits are related to different fibre types. Some fibres that are well tolerated by IBS
individuals include psyllium, linseeds, oat bran [41,42]. Due to individual heterogeneity,
IBS patients should consider their own tolerability, the fibre amount, and preparation (e.g.,
whole/ground seeds) when using different fibres to improve or manage symptoms. For
instance, patients need to ensure adequate water consumption when adding psyllium to
their food due to its soluble and viscous characteristics.
1.4. The Relationship of Dietary Fibre, SCFA, Sleep, Mental Health, and the Gut Microbiome
The functionality of dietary fibres in the human gastrointestinal tract is determined
by their physiochemical properties, such as solubility, viscosity, and fermentability [42].
Moreover, the amount and type of fibre residue escaping small intestinal digestion and
reaching the colon drives the extent of fermentation [43]. For example, the location of gut
microbial fermentation of psyllium, with its soluble and low fermentable characteristics,
occurs along the length of the colon to produce SCFA, whereas the fermentation of resistant
starch (RS) occurs more proximally in the colon due to its higher fermentability and low
solubility (or insolubility depends on the types of RS) [41]. Specific gut microbes tailor
the degradation and fermentation of specific fermentable fibres [44]. Some foods are
associated with a higher abundance of specific beneficial gut microbes; for example: a
higher abundance of Faecalibacterium prausnitzii has been positively associated with a
higher intake of fruits, red wine, and oily fish; whereas Roseburia hominis increased on a
diet containing nuts, oily fish, vegetables, legume, cereals [45].
Specifically, Faecalibacterium prausnitzii, a commensal bacterium, is a suitable biomarker
in certain gut conditions, such as inflammatory bowel disease [46], and may be a suitable
candidate as a future probiotic [47]. Faecalibacterium prausnitzii-derived metabolites, such as
butyrate, can restore the impaired intestinal barrier structure and function [48]. Faecalibac-
terium prausnitzii has been associated with IBS as well as other diseases and disorders, such
as colorectal cancer, obesity, type 2 diabetes, non-alcoholic fatty liver disease, Alzheimer’s
and Parkinson’s disease, major depressive disorder, and bipolar disorder [46]. In an ob-
servational case-control pilot study evaluating gut microbial composition in children with
obstructive sleep apnoea syndrome (OSAS), the abundance of Faecalibacterium prausnitzii
was reduced in the OSAS cohort, compared with the healthy subjects [49]. The genus of
Faecalibacterium was also associated with reduced depressive symptoms and better sleep in
patients with bipolar disorder [50]. Taking the specific microbe as an example can show
the existence of intertwined associations among gut microbiota, sleep, and mental health.
SCFAs are one of the pivotal links, though the whole mechanisms remain unclear.
SCFAs are generated from gut microbial fermentation throughout the colon [51],
with SCFA levels declining along the large intestine because of the rapid uptake and
metabolisation by colonocytes [52], with only an estimated 5% of bacteria-derived SCFA
appearing in the stool [53]. Within all three major SCFAs components, butyrate is the
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most effective in the trophic properties and provides the primary fuel for the colonic
epithelial cells to maintain their growth and integrity [54,55]. Butyrate contributes to
maintaining host health with the anti-inflammatory and antioxidant features that affect the
immune system [56] and prevent diseases such as colorectal cancer [57,58], diabetes, and
obesity [59]. Butyrate concentration is mainly dependent on the quantity and quality of
dietary fibre reaching the colon [60]. Research has shown higher concentrations of butyrate
in human faeces to be associated with greater fibre intake [61]. Foods that are rich in dietary
fibre, such as nuts, fruit, vegetable, and cereal, are also linked to a greater abundance of
SCFA producers in the human gut microbiota [45]. Since a low-FODMAP diet may result
in reducing intake of dietary fibre long term [62], and studies have shown that people
following this diet have a lower production of butyrate in the faeces [63], the potential long-
term influence of low-FODMAP diet/low intake of fibre among IBS population requires
further research.
National data from a U.S. adults survey has quantitively demonstrated an association
between the daily intake of total fibre and sleep duration, where <5 h sleep, 5–6 h sleep,
and 9+ h sleep were associated with decreased intake at levels of 13.2 ± 10.1 g (mean
± standard deviation), 15.9 ± 10.9 g and 14.2 ± 8.7 g, respectively, whereas adults with
normal sleep (7–8 h) had the highest intake at 16.6 ± 9.6 g [64]. As mentioned earlier,
the LFD reduces the intake of fermentable fibres, which can lead to alterations of the gut
microbiota and a reduction in fermentation in the large bowel, and as such can reduce
the production of short-chain fatty acids (SCFA) that support colonic integrity and colono-
cytes growth [23,63,65–67]. Microbiota-derived SCFA has also been suggested to enhance
sleep [68] and modulate host circadian clocks [69] in animal studies. This related to the
circadian clock maintaining mammalian homeostasis and rhythmic physiology, such as the
sleep-wake cycle, eating, and fasting [70]. Gut microbiome composition and SCFA is asso-
ciated with sleep physiology, where microbial alterations relate to sleep problems [71–73],
and also play a pivotal role in human mental health conditions [74–78]. A recent study
has found that acute psychological stress can increase intestinal permeability in healthy
volunteers [79], which can be decreased by probiotics and prebiotics [75]. Prebiotics and
probiotics also have shown the capacity to improve mental health, including depression
and anxiety [75], although the pathway and mechanism behind this remain unclear. There-
fore, it is important to expand IBS-related research to cover all these areas together and to
identify the relationships among them.
1.5. The Current Gap and the Purpose of This Scoping Review
IBS patients strive to manage their symptoms and normalise or improve their dys-
biotic gut microbiota to experience better sleep and mental health, all bi-directionally
linked to the gut microbiota (Figure 1). Emerging research based on healthy populations
has focused on gut microbiota modulation via particular dietary fibre or specific prebi-
otics supplements [80–82]. These studies have identified promising and cost-effective
approaches to improve human health. A few reviews recently published in 2020 have
identified the associations among certain foods, nutrients, or diet intervention and their
effects on sleep outcomes; however, they were all based on healthy adults [83,84]. How-
ever, among IBS populations, limited data are available. A few studies have focused on
diet management or fibre supplementation. Their findings were specifically limited to
gastrointestinal (GI) symptom improvement [42,85–87] rather than improvement in gut
health, as well as in sleep and mental health. Accordingly, a gap remains in the research
specific to IBS populations, particularly related to fibre-related intervention and its effects
on the gut microbiota, sleep, and mental health. Hence, a scoping review that locates the
existing evidence and identifies gaps in this area is essential to provide further direction
regarding future explorations.
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Figure 1. PRISMA flow chart of articles identification and inclusion.
The aim of this scoping review is to map the research evidence that has provided IBS
patients with dietary fibre-related intervention and described their effects on at least two of
the following three outcomes: gut microbiota, sleep, or mental health.
2. Materials and Methods
2.1. Search Strategy
This review follows a scoping review protocol from the 2020 version of the Joanna
Briggs Institute (JBI) manual [88], adhering to the Preferred Reporting Items for System-
atic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) reporting
standards [89]. A systematic search strategy was conducted to retrieve published research
about fibre-relevant interventions in IBS patients recording outcomes on gut microbiota,
sleep, and mental health. A literature search was performed on 26 February 2021, using
five digital databases: MEDLINE, Embase, Web of Science, APA Psyc info, and CINAHL.
The keywords used in the search are detailed in Table 1. Boolean operators (AND and OR),
as well as the truncation, were used when each string was built for literature searching
(Table 1). A complete set of terminology used in searching the literature combined at least
four concepts with IBS and fibre as fixed concepts: IBS AND fibre AND gut microbiota
AND sleep, IBS AND fibre AND gut microbiota AND mental health, IBS AND fibre AND
sleep AND mental health, and IBS AND fibre AND gut microbiota AND sleep AND
mental health.
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Table 1. Search keywords.







diet * OR diet therapy OR diet *
fibre OR diet * fibre OR fib *
supplement OR fermentable




Gut microbio * OR
gastrointestinal
microbiome OR
microbio * OR gut
flora OR dysbiosis
sleep * OR insomnia OR
sleep disorder * OR sleep
problem * OR sleep
deprivation OR sleep
fragmentation * OR sleep
disturbance OR sleep




Truncation (*) was applied in the prosses of databases searching.
2.2. Selection Criteria
Articles were included if they were original research papers in IBS patients and had a
fibre-related intervention and meet the inclusion criteria and did not meet the exclusion
criteria, as detailed below.
Inclusion criteria:
1. The outcomes consisted of at least two out of three topics of: gut microbiota, sleep,
and mental health.
2. Study types included peer-reviewed case-controls, cross-sectional studies, cohort




(2) Reviews, case reports, and systematic reviews;
(3) Subjects are non-adults;
(4) Non-English articles;
(5) Articles without full text or study design or results are not available;
(6) Interventions with probiotics, synbiotics, or medicine.
2.3. Study Selection
Records retrieved across the five searched databases were imported to the online
reference management platform COVIDENCE [90]. After duplicates were automatically
removed via COVIDENCE, records were screened using title and abstract, followed by
a full-text article assessment against the inclusion and exclusion criteria by the first and
second reviewers. The third and the fourth reviewers were consulted if the decision of any
article remained disputed until a consensus was reached for all articles.
2.4. Data Extraction
Data were extracted and summarised from selected articles and transferred to a form
with the headings: title, first author, country, year, type of study, sample size (N), as well as
information of participants relating to mean age, age range, IBS subtypes, Rome diagnosis
version, baseline fibre intake (g/day); interventions and group setting, and the outcomes in
gut microbiota, sleep, and mental health as well as adverse effects. As the scoping review
focused on a minimum of two out of three topics (gut microbiota, sleep, and mental health),
only relevant outcomes were summarised and reported. Therefore, findings around other
aspects such as quality of life and bowel symptoms were not extracted and reported.
3. Results
Based on the search strategy, 146 articles were selected from the databases, with two
further articles from other sources, resulting in 148 records identified for screening via
COVIDENCE. After the automatic removal of duplicates by COVIDENCE, 128 articles
were scanned using titles and abstracts. During the first screening phase, 73 were excluded,
leaving 55 articles to be assessed for eligibility in the second phase, where 50 articles were
excluded (Figure 1). As a result, five articles were included in the scoping review (Table 2).
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NA
Abbreviations: N: sample size. NA: not available. IBS-D: diarrhoea dominant IBS; IBS-C: constipation dominant IBS; IBS-A: alternating IBS; IBS-U: unclassified IBS; IBS-M: mixed bowel habits IBS. HAD/HADS:
Hospital Anxiety and Depression Scale. scFOS: short-chain fructooligosaccharides. mNICE: modified diet recommended by the National Institute for Health and Care Excellence. PSQI: Pittsburgh Sleep Quality
Index. * The mNICE group was instructed to eat small frequent meals and avoid trigger foods, excess alcohol, and caffeine. ** The mean ages reported separately in two groups (41 in scFOS group, 42.4 in placebo
group). *** State-Trait Personality Inventory: psychological indices concerning depression and anxiety.
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3.1. Characteristics of Included Studies
3.1.1. Study Designs and Interventions
Of the five studies, three were randomised controlled trials, one was a prospective
observational study, and one was a single-arm interventional study. Two studies added
dietary supplementation to the habitual diets of participants, while the other three provided
LFD intervention via dietitian or nutritionist consultation and instruction (Table 2).
3.1.2. Setting and Participants Characteristics
The studies included in the scoping review were performed in the USA [91], France
and Spain [92], U.K. [93], Australia and New Zealand [94], and Italy [95]. Four of the
five studies were published within the last five years, three in 2017, one in 2019, and the
remaining study in 2009. The Rome diagnosis version used was the current version at
the time of the study. Only one study (published in 2009) used Rome II, while the other
four used Rome III, which was released in 2006 and introduced the classification of four
subtypes of IBS based on stool consistency [96].
The mean age of participants across the five studies was 43.9 years. The upper limit of
age ranged from 60 to 79 across the five studies, where the lower limit was the same at 18
years except for one study where it was 16 years. One study limited participants to females
with IBS-D, while the other four included both genders with all IBS subtypes.
3.1.3. Dietary Fibre Intake Data
Two out of five studies reported data of dietary fibre intake, including baseline and
treatment period. Bellini et al. implemented an 8-week LFD in IBS volunteers, and no
statistical significance was found between the two time points, even though mean intake
during LFD (17.5 ± 7.3 g) was lower than the one at baseline (20.5 ± 10.7 g/day). The
other study using GOS as the treatment reported that the fibre intake remained unchanged
among the groups (placebo group and prebiotic groups) during the course of the study.
Eswaran et al. reported that nutrient intake was similar between the LFD group and
the control group, while no data were provided. The other two studies did not report
nutrient data.
3.2. Outcomes Combining Gut Microbiota and Mental Health
No studies in this review included all three topics or the two specific topics of gut
microbiota and sleep.
Two studies identified gut microbiota and mental health in their results. Azpiroz
et al. (2017) [92] assessed the effects of 5 g/d short-chain fructooligosaccharides (scFOS) or
placebo for 4 weeks in IBS patients classified using the Rome III criteria. In contrast, Silk
et al. (2009) [93] conducted an RCT with a crossover design between three groups (two
treatment and one placebo), introducing 3.5 g or 7 g of trans-galactooligosaccharide (GOS)
in patients with Rome II positive IBS. All subjects in the above study had a 2-week baseline,
then were randomised into three groups for the two 4-week interventions with a 2-week
washout phase in between. All participants started on a 4-week placebo treatment and,
following the 2-week washout, then proceeded on a 4-week treatment (3.5 g GOS in Group
I; 7 g GOS in Group II; 7 g placebo in Group III).
Stool samples were collected pre-and post-intervention for faecal microbiota analysis
in both studies. qPCR was conducted in Azpiroz et al.’s research for describing the dom-
inant taxonomic groups of the faecal microbiota. In contrast, Silk et al. used fluorescent
in situ hybridisation to determine total bacterial counts and individual groups of faecal
bacteria. A key finding in both studies despite prebiotics supplement (scFOS and GOS)
was an increased abundance of faecal bifidobacteria. Additionally, the 4-week administra-
tions of 3.5 g and 7 g GOS resulted in a significant increase in the relative proportion of
Bifidobacterium spp compared to the placebo and the increase higher in the 7 g GOS group.
In the scFOS study, the increase in bifidobacteria was significantly increased at the end
of the study within the scFOS group, but this difference was not seen between the scFOS
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and placebo groups. Both studies assessed mental health using a validated questionnaire
(Hospital Anxiety Depression Scale (HADS)), where both prebiotics of 5 g/day scFOS and
7 g/day GOS resulted in a significant reduction in HADS anxiety scores.
3.3. Outcomes Combining Sleep and Mental Health
Three studies included sleep and mental health as primary outcomes to determine
the effectiveness of LFD as a treatment, all of which were delivered via qualified di-
etitians/nutritionists. Eswaran et al. [91] compared a 4-week LFD to the mNICE diet
(modified diet recommended by the National Institute for Health and Care Excellence) [33].
In contrast, Bellini et al. [95] compared before and after an 8-week LFD in a single-arm
study, while Kortlever et al. [94] provided participants with a dietitian’s consultation of
LFD at baseline with follow-up at 6 and 26 weeks. The Rome III criteria were used to
diagnose patients in all three studies.
No objective sleep measures were used in the five studies. Sleep was measured using
subjective self-report questionnaires, including daily sleep quality ratings and pre/post
modified sleep questionnaires, Pittsburgh Sleep Quality Index (PSQI), and Karolinska Sleep
Questionnaire, respectively. For mental health assessment, HADS was applied in both
Eswaran’s and Bellini’s studies [91,95], while Kortlever et al. assessed mental health using
the State-Trait Personality Inventory (psychological indices concerning depression and
anxiety). Notably, anxiety improved in all three of these studies. Eswaran et al. reported
that sleep, anxiety, and depression all improved in the LFD group compared to the baseline,
whereas only anxiety improved in the mNICE group. After 8-week of LFD, Bellini et al.
identified an improvement in anxiety but not depression using HADS. They also did
not record any improvements in sleep quality using PSQI. Kortlever et al.’s prospective
observational study found improvement in anxiety after both 6 weeks and 26 weeks and in
depression scores at 26 weeks, but no change was detected in sleep.
4. Discussion
This scoping review aims to survey the current evidence, including two out of the
three primary outcomes of interest, namely gut microbiota, sleep, and mental health in
IBS populations with dietary intervention. According to our results, none of the fibre-
related interventional studies investigated all three outcomes and gut microbiota and sleep
in combination. Five research studies were included, with two studies examining the
relationship of the gut microbiota and mental health and three studies including sleep
and mental health in their analysis. As scientific discovery covering gut microbiota and
linking it to brain and behaviour is still being established, the association between sleep
and diet [83], as well as mental health and gut microbiota [74,97], are gradually becoming
acknowledged. Since diet is regarded as the main determiner of human gut microbiota [98],
the relationship between diet, sleep, and mental health requires further consideration of
gut microbiota in order to close the knowledge gap.
In all five studies included in this scoping review, only improved self-reported anxi-
ety for IBS volunteers when following a fibre-related intervention was shared across all
studies. Many animal studies have supported similar findings, where a prebiotic com-
bination of GOS and polydextrose (PDX) has been shown to increase Lactobacillus spp.
and Bifidobacterium spp. in rat faeces, attenuating anxiety-like behaviours [99]. Simi-
larly, early-life supplementation of GOS and PDX can distinctly reduce stress-induced
behaviours in mice [100]. Human studies are also attempting to determine the mecha-
nism and interrelation between anxiety-depressive states, gut microbiota, and IBS itself,
which has been associated with alterations in stress-induced inflammation, gut-oriented
hormones such as serotonin and peptide YY (PYY), as well as microbial-mediated metabo-
lites such as SCFA [75,101]. It is still unknown as to whether there exists a certain gut
microbial profile that is linked to positive or negative mental health [74] and whether the
human gut microbiota acts as a communicative hub [74,76] or acts as an aetiologic origin
of disordered mental health [77,78]. Nonetheless, gut microbiota modulation remains a
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valuable strategy for people with mental health issues [102]. Encouraging improvement
has been achieved simply via dietary adaptations, adding prebiotics and/or probiotics in
appropriate amounts [103,104], where long-term sustained benefits undoubtedly require
considerations and adjustments in the overall dietary pattern.
4.1. Dietary Fibre Intake in IBS
Only two studies [93,95] in this scoping review reported on baseline dietary fibre
intake (Table 2), where participants in both failed to meet the dietary reference value
regardless of national dietary recommendations. Similarly, the findings from Staudacher
et al. [35] demonstrate that many IBS individuals did not adhere to the recommended
fibre intake. Notably, this trend is not unique to IBS populations as it commonly occurs
in the general population. The mean fibre intake among U.K. adults (19–65 years) was
19 g/day based on reports in 2015 and 2018/2019 [105], where only 9% of adults consumed
the daily recommended amount of fibre (30 g) [106]. Another U.K. research using data
of supermarket sales transaction of the whole year of 2016 (n = 299,260) found out that
the average fibre intake was 16 g/day, where the most, 21 g/day, was seen in people
with “fruity” dietary pattern (defined as 7 of the top 10 purchased items being types
of fruit) [107]. Among U.S. adults (>19 years of age), dietary fibre intake in 2009 was
13.7 g/day in females and 17.6 g/day in males, with only 6% and <3% meeting the AI
recommendation, respectively [108]. In the countries of the Eastern Mediterranean region,
the average daily intake of fibre was 21.8 g/day (95% confidence interval: 19.6–24.1),
according to the finding of a recent meta-analysis based on 43 studies (n = 72,534 subjects)
published in recent nine years [109]. Accordingly, low dietary fibre intake in the general
population appears to be a global issue.
Among IBS populations, certain dietary fibres [86] have been listed as a tool for overall
symptom improvement, depending on physicochemical characteristics, including viscosity,
solubility, and fermentability. A narrative review of meta-analyses published in March
2020 [110] found that four out of five meta-analyses suggested that fibre supplementation
could provide significant clinical improvement via the Global Assessment of IBS Symptoms
evaluation. This is also reflected in the recent Japanese IBS treatment guidelines suggesting
bulking polymers or dietary fibre as an effective IBS treatment ranked as Level A evidence—
strong recommendation [111], although no specific amount was specified.
In summary, what is currently lacking is probably not the exploration of optimal
quantity of fibre intake, but rather the exploration of how to increase fibre intake in IBS
individuals for symptoms-attenuation or non-exacerbation of symptoms.
4.2. Dietary Fibre Administration for People with IBS
With their relatively safe and inexpensive characteristics, dietary fibres can be widely
applied to improve symptoms for people with IBS [87]. However, it may be difficult for
IBS individuals to find replacement foods that are rich in fibre and potentially low in
FODMAP [112] or ones they can tolerate well in order to avoid symptom attenuation.
Therefore, it would be favourable and cost-effective for patients if they can manage the dis-
order via a combination of certain isolated fibres that optimises their gut microenvironment
and gut function in place of whole foods. Clinically, sufficient guidance and education are
also required so that patients can optimise their daily fibre intake without symptoms exac-
erbation, as well as can ensure the overall diet quality, overcome the potential challenges
and minimise the possible detrimental effects of applied LFD [113].
There is evidence in the literature that a combination of isolated fibres, as a diet sup-
plement, may be an option for IBS patients to improve their gut health. In IBS patients,
short-chained carbohydrates resistant to digestion in the small intestine are rapidly fer-
mentable in the proximal colon, where they can aggravate gastro-symptoms. However, in
animal studies, it has been demonstrated that the rapid fermentation of RS can be mediated
by moving the fermentation down towards the distal colon using psyllium [114]. Morita
et al. [114] demonstrated in rats that psyllium can shift the RS2 (high amylose maize starch)
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fermentation further distally, by which butyrate production appears increased both in
the distal colonic region and faeces. This is due to psyllium’s slow fermentability, strong
gel-forming, and water-holding capacity, which traps RS granules and protects against
proximal colonic fermentation, thereby delivering RS to the distal colon [114]. Similarly,
the effects of RS-fermentation delay and higher butyrate production were also observed in
a pig study using wheat bran and RS [115]. This has also been demonstrated in healthy
volunteers where the supplementation of wheat bran combined with RS [116,117] can mod-
ulate gut microbiota, increasing butyrate and butyrate-producing bacteria. Interestingly, in
contrast to wheat bran, psyllium is well tolerated by IBS subjects and has been deemed
as an effective non-pharmaceutical management tool by authoritative bodies to improve
overall symptoms, particularly for IBS-C patients [19,118]. The favourable effects of the
gut-oriented metabolites relevant to the administration of dietary fibre in IBS individuals
require further exploration.
Accordingly, it appears promising that IBS management can be enhanced with fibre
co-administration that maximise the effects of dysbiosis normalisation while improving
symptoms [42]. This may be a future direction for IBS-related research. In this regard, the
therapeutic function and tolerability also need to be taken into consideration.
4.3. Evolution of Diagnosis Guideline and Potential Impacts
In accordance with the results of this scoping review, four of the five included studies
used the Rome III criteria, while only one remaining study used Rome II. Therefore, IBS-
relevant research using the newest Rome IV criteria is required. While the Rome IV version
was published 10 years after its predecessor in 2016, as a result of its stricter criteria, it
may prove an obstacle for researchers in recruiting patients with IBS. According to a meta-
analysis published in 2020, the global prevalence of IBS dropped from 9.2% to 3.8%, which
would mean that part of existing IBS populations diagnosed by Rome III would technically
be reclassified, based on the Rome IV, as “no bowel disorder or unspecified functional
bowel disorders” [119]. This has led the Vice-Chair of Administration of the University of
Tennessee Health Science Center in 2020 to raise a query as to whether the Rome criteria is
a sound diagnosis for GI disorders [120].
Nonetheless, whether one in 11 (according to the Rome III criteria) or one in 26 people
(according to the Rome IV criteria) are classified as suffering from IBS [119], these people
still require optimal solutions and support. Based on patient reports of real-life experiences,
IBS patients have struggled with various physical (i.e., GI symptoms and fatigue), psycho-
logical (i.e., depression and anxiety), and social (i.e., avoiding activities and long-distance
travel, limited food choices) consequences [121]. Hence, these factors further function as
stressors and triggers, that together with their precursors, constitute a vicious cycle.
4.4. Sleep Hierarchical Assessment Methods
The wide availability and application of wearable sleep monitoring technologies, such
as sleep tracking devices, have exhibited high performance in sleep-wake detection [122].
These devices are home-based and cost-effective have enabled an increase in sleep-related
research [123,124], facilitating multi-disciplinary research that provides insight into sleep
changes based on variable study settings.
With regards to sleep as an outcome measure in this scoping review, only the LFD
group in Eswaran’s research showed an improvement. However, no objective sleep mea-
sures were applied in any of the studies included. Possible explanations for the lack of
observable change could be due to either changes in sleep not occurring, changes not being
identified, or studies being underpowered to detect a change. These factors cannot be ne-
glected. Every method for assessing sleep has potential strengths and shortcomings, where
there exists a relative hierarchy in order of accuracy, including: polysomnography (PSG)-
gold standard > contact devices > contactless devices > questionnaires [125] (Figure 2). In
relative terms, due to subjective perception about one’s own quality of sleep and memory
bias, it is likely that data obtained in sleep questionnaires can be biased and inconsistent as
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compared with data from validated devices [125]. Therefore, in future research, it would
be beneficial to combine subjective and objective methods of data collection in order to
obtain more reliable and accurate results in IBS-related studies.
Figure 2. A relative hierarchy in order of sleep assessment methods.
Diet-derived sleep improvement has also been previously documented [126], and
healthy adults’ sleep can be negatively impacted when people shift their diet towards low
fibre and high saturated fat and sugar intake [127]. Animal studies have shown that dietary
prebiotics [128] and their metabolite, butyrate [68], can improve sleep.
4.5. Limitations
The scoping review extracted the outcomes on the three topics of interest (gut micro-
biota, sleep, and mental health) rather than all outcomes in the included studies. As diet
is the main determinant of human gut microbiota, this review only targeted fibre-related
interventions as one of the inclusive criteria, where other treatments such as psychotherapy,
including gut-focused hypnotherapy, cognitive behaviour therapy (CBT), and mindful-
ness were not assessed. Finally, the review limited the subjects studied to IBS adults
only, where children and elderly participants and animal studies were not included in the
scoping exercise.
4.6. Future Research Recommendations
With regard to sleep assessment specifically, a high level of accuracy and reliability of
sleep measures, combining objective and subjective methods if applicable, is essential to
ensure the quality of data collected. Additionally, studies with psychotherapy treatments
or behavioural therapies for IBS could also be mapped in future reviews targeting the
three themes as outcomes for a better understanding of the link, if any exists, between
gut microbiota and sleep and mental health. Notably, effects resulted from diet-related
intervention in gut microbiota and sleep require considerations in IBS subtypes, habitual
diet, and the baseline (pre-interventional) gut microbial phenotype [74]. This is related to
host interactive influence, where different microbial compositions may result in similar
functions and vice versa [74]; while the intertwined association between host habitual diet
and gut microbiota [45,98], as well as sleep and gut microbes [71,73,129], has not been
fully identified.
During the searching process for this review, three study protocols were identified that
targeted all three themes together [130], with one adding structural magnetic resonance
imaging (MRI) of the human brain [131] and another creating a massive prospective
cohort of people with IBS, inflammatory bowel disease, and healthy individuals combing
genetic, microbiome, and metabolomic profiles [132]. All these scientific advancements are
promising, potentially introducing a new era of “microbiome literacy” from “food literacy”.
For IBS non-pharmaceutical management, it is worthwhile to explore dual or multi-
administration of dietary fibres that are well tolerated, therapeutically functional, and
capable of promoting the entire or local intestinal microbial environment. Even though a
one-size-fits-all treatment for IBS individuals does not exist, individualising/personalising
dietary plans can be an optimal and economically feasible solution for this population. It is
likely that the gut microbiome is the main determinant of the diet-health relationships [133].
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Therefore, further exploration of the “pieces of the puzzle” around gut microbiota, sleep,
mental health, and habitual diet in IBS is still required.
5. Conclusions
This scoping review has highlighted the lack of IBS-relevant research targeting the
three themes of gut microbiota, sleep, and mental health as outcomes when administering
a dietary intervention. Future work should continue to focus on diet-related interventions,
either for alterations in a whole dietary pattern or for specific components of the diet or
supplementation as needed to manage IBS symptoms with emphasis on improving the dys-
biotic gut environment that can further improve sleep and mental health outcomes among
IBS populations. Additionally, the application of objective sleep assessment methods is
required to detect sleep change with more accuracy and less bias.
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